Program
Levetiracetam
Also written as “Levetiracetam (Keppra)”, “levetiracetam” and “Levetiracetam 250 mg”.
Its studies are mostly in Epilepsy · Epilepsies, Partial · Seizures · Cognitive Dysfunction · Epilepsy, Generalized, led by 8 companies.
Drug pageLevetiracetam: every studyMany companies study it; this page follows only the 72 they lead. All 204 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCBits history only | 570 open or running | phase 4since Sep 8, 2005 | Mar 3, 2005 | none ahead |
| Hikma Pharmaceuticalsits history only | 40 open or running | no phasesince Jan 15, 2009 | Jan 15, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Feb 20, 2009 | Feb 20, 2009 | none ahead |
| AgeneBioits history only | 20 open or running | phase 3since Mar 28, 2018 | Mar 28, 2018 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Jul 6, 2011 | Jul 6, 2011 | none ahead |
| Desitin Arzneimittelits history only | 10 open or running | phase 1since Dec 1, 2025 | Dec 1, 2025 | none ahead |
| Novartis | 10 open or running | phase 1since Jul 24, 2009 | Jul 24, 2009 | none ahead |
Also a collaborator on its studies: PRA Health Sciences and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 24, 2009First study: phase 1 study in SeizuresFirst studyNCT00946751 · 20 enrolled
TargetBeta
“Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker”ChEMBL 37, by rule
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00946751Seizures | 1 | Completed | Mar 2004 | 20 |
How it is read
Names in the registry
- “Levetiracetam”, 52 entries
- “Levetiracetam (Keppra)”, 4 entries
- “levetiracetam”, 3 entries
- “Levetiracetam 250 mg”, 3 entries
- “Levetiracetam 500 mg”, 3 entries
Conditions, from the studies’ own filings
- Epilepsy, 26 studies
- Epilepsies, Partial, 13 studies
- Seizures, 8 studies
- Cognitive Dysfunction, 2 studies
- Epilepsy, Generalized, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.